Comparison of "selective" opiate receptor antagonists on the isolated mouse vas deferens
dc.contributor.author | Smith, Charles B. | en_US |
dc.contributor.author | Bennett-Kelly, L. | en_US |
dc.contributor.author | Woods, James H. | en_US |
dc.date.accessioned | 2006-04-07T18:16:28Z | |
dc.date.available | 2006-04-07T18:16:28Z | |
dc.date.issued | 1984-12 | en_US |
dc.identifier.citation | Smith, C. B., Bennett-Kelly, L., Woods, J. H. (1984/12)."Comparison of "selective" opiate receptor antagonists on the isolated mouse vas deferens." Neuropeptides 5(1-3): 161-164. <http://hdl.handle.net/2027.42/24610> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6WNR-4C48C8T-8X/2/562dd126bad8f8e9524a81bc0e8eaa2f | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/24610 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=6099488&dopt=citation | en_US |
dc.description.abstract | The selectivity and relative potencics of opiate receptor antagonists were compared on the mouse vas deferens preparation. ICI-174864 was found to be a highly selective antagonist at delta opiate receptors equal in potency to naltrexone in blocking the actions of delta agonists. Although less potent than naltrexone, beta-funal trexamine (beta-FNA) and Mr-1452, like naltrexone, were less selective in that they blocked the actions of mu, delta and kappa agonists. The relative potencies of beta-FNA and Mr-1452 in antagonizing the three types of agonists also were similar to naltrexone. | en_US |
dc.format.extent | 291023 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Comparison of "selective" opiate receptor antagonists on the isolated mouse vas deferens | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109, USA | en_US |
dc.contributor.affiliationum | Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109, USA | en_US |
dc.contributor.affiliationum | Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109, USA | en_US |
dc.identifier.pmid | 6099488 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/24610/1/0000020.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0143-4179(84)90052-0 | en_US |
dc.identifier.source | Neuropeptides | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.